Abstract
In a deal potentially worth $415 million, Biogen and C4 Therapeutics will jointly develop protein degraders for neurological conditions, including Alzheimer’s and Parkinson’s diseases. While conventional small-molecule drugs typically inhibit protein function, degraders force bad-behaving proteins to be tagged for the cellular trash bin. Separately, Biogen will work with Skyhawk Therapeutics to develop small molecules that modulate RNA splicing—the way that stretches of RNA are pieced together to form the code for building a protein. Skyhawk will get $74 million up front to develop treatments for neurological diseases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
